Evolução clínica dos pacientes com COVID-10: impacto da anticoagulação

Autores

DOI:

https://doi.org/10.33448/rsd-v11i9.31423

Palavras-chave:

COVID-19; Evolução; Anticoagulação; Unidade de Terapia Intensiva.

Resumo

Coronavirus disease 19 (COVID-19) mainly targets the respiratory system and progresses to a severe form in up to 16% of in-patients, causing thromboembolic disorders, sepsis and death. In severe cases, a pro-inflammatory cytokines “storm” develops that trigger clotting pathways disorders and thromboembolism. The objective of this study was to assess the evolution of COVID-19 patients, admitted to an intensive care unit (ICU), and to observe the impacts of anticoagulation therapy in those patients with critical parameters. This was a cross-sectional study, reviewing the medical records of patients admitted to the ICU, with a confirmed diagnosis of COVID-19, in the period between March and December 2020, in a general hospital in southern Brazil. Among the 231 patients assessed, a mortality rate of 66.2% was recorded. Among the most relevant findings associated with death are the presence of heart disease and previous systemic arterial hypertension (SAH), clinical evolution with renal failure and creatinine clearance <30 and hyperbilirubinemia. Out of the 103 patients who were on anticoagulation therapy under critical parameters, 88 died. Advanced age (≥ 60 years), presence of comorbidities, complications during hospital stay, laboratory alterations and evolution with transinfectious hepatitis were associated with mortality. Anticoagulation therapy under critical parameters was associated with a higher death rate, with clinical evolution between ICU admission and fatal outcome after two weeks of infection.

Referências

Asakura, H., Takahashi, H., Uchiyama, T., Eguchi, Y., Okamoto, K., Kawasugi, K., Madoiwa, S., Wada, H., & DIC subcommittee of the Japanese Society on Thrombosis and Hemostasis (2016). Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thrombosis journal, 14, 42.

Chai, X., Hu, L., Zhang, Y., Han, W., Lu, Z., Ke, A., ... & Lan, F. (2020). Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. biorxiv.

Chan, L., Chaudhary, K., Saha, A., Chauhan, K., Vaid, A., Zhao, S., Paranjpe, I., Somani, S., Richter, F., Miotto, R., Lala, A., Kia, A., Timsina, P., Li, L., Freeman, R., Chen, R., Narula, J., Just, A. C., Horowitz, C., Fayad, Z., … Mount Sinai COVID Informatics Center (MSCIC) (2021). AKI in Hospitalized Patients with COVID-19. Journal of the American Society of Nephrology : JASN, 32(1), 151–160.

Cheng, Y., Luo, R., Wang, K., Zhang, M., Wang, Z., Dong, L., Li, J., Yao, Y., Ge, S., & Xu, G. (2020). Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney international, 97(5), 829–838.

Cronin, M., Dengler, N., Krauss, E. S., Segal, A., Wei, N., Daly, M., ... & Caprini, J. A. (2019). Completion of the updated Caprini risk assessment model (2013 version). Clinical and Applied Thrombosis/Hemostasis, 25, 1076029619838052.

Darzi, A. J., Repp, A. B., Spencer, F. A., Morsi, R. Z., Charide, R., Etxeandia-Ikobaltzeta, I., Bauer, K. A., Burnett, A. E., Cushman, M., Dentali, F., Kahn, S. R., Rezende, S. M., Zakai, N. A., Agarwal, A., Karam, S. G., Lotfi, T., Wiercioch, W., Waziry, R., Iorio, A., Akl, E. A., … Schünemann, H. J. (2020). Risk-assessment models for VTE and bleeding in hospitalized medical patients: an overview of systematic reviews. Blood advances, 4(19), 4929–4944.

Ertuğlu, L. A., Kanbay, A., Afşar, B., Elsürer Afşar, R., & Kanbay, M. (2020). COVID-19 and acute kidney injury. COVID-19 ve akut böbrek hasarı. Tuberkuloz ve toraks, 68(4), 407–418.

Espinosa, O. A., Zanetti, A., Antunes, E. F., Longhi, F. G., Matos, T. A., & Battaglini, P. F. (2020). Prevalence of comorbidities in patients and mortality cases affected by SARS-CoV2: a systematic review and meta-analysis. Revista do Instituto de Medicina Tropical de Sao Paulo, 62, e43.

Goha, A., Mezue, K., Edwards, P., Nunura, F., Baugh, D., & Madu, E. (2020). COVID-19 and the heart: An update for clinicians. Clinical cardiology, 43(11), 1216–1222.

Guan, W. J., Liang, W. H., Zhao, Y., Liang, H. R., Chen, Z. S., Li, Y. M., Liu, X. Q., Chen, R. C., Tang, C. L., Wang, T., Ou, C. Q., Li, L., Chen, P. Y., Sang, L., Wang, W., Li, J. F., Li, C. C., Ou, L. M., Cheng, B., Xiong, S., … China Medical Treatment Expert Group for COVID-19 (2020). Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. The European respiratory journal, 55(5), 2000547.

Hadid, T., Kafri, Z., & Al-Katib, A. (2021). Coagulation and anticoagulation in COVID-19. Blood reviews, 47, 100761.

Hippensteel, J. A., LaRiviere, W. B., Colbert, J. F., Langouët-Astrié, C. J., & Schmidt, E. P. (2020). Heparin as a therapy for COVID-19: current evidence and future possibilities. American journal of physiology. Lung cellular and molecular physiology, 319(2), L211–L217.

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Xiao, Y., … Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England), 395(10223), 497–506.

Iba, T., Nisio, M. D., Levy, J. H., Kitamura, N., & Thachil, J. (2017). New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ open, 7(9), e017046.

Klok, F. A., Kruip, M., van der Meer, N., Arbous, M. S., Gommers, D., Kant, K. M., Kaptein, F., van Paassen, J., Stals, M., Huisman, M. V., & Endeman, H. (2020). Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis research, 191, 145–147.

Kudose, S., Batal, I., Santoriello, D., Xu, K., Barasch, J., Peleg, Y., Canetta, P., Ratner, L. E., Marasa, M., Gharavi, A. G., Stokes, M. B., Markowitz, G. S., & D'Agati, V. D. (2020). Kidney Biopsy Findings in Patients with COVID-19. Journal of the American Society of Nephrology : JASN, 31(9), 1959–1968.

Levey, A. S., Becker, C., & Inker, L. A. (2015). Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. JAMA, 313(8), 837–846.

Li, J., Huang, D. Q., Zou, B., Yang, H., Hui, W. Z., Rui, F., Yee, N., Liu, C., Nerurkar, S. N., Kai, J., Teng, M., Li, X., Zeng, H., Borghi, J. A., Henry, L., Cheung, R., & Nguyen, M. H. (2021). Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. Journal of medical virology, 93(3), 1449–1458.

Li, X., Xu, S., Yu, M., Wang, K., Tao, Y., Zhou, Y., Shi, J., Zhou, M., Wu, B., Yang, Z., Zhang, C., Yue, J., Zhang, Z., Renz, H., Liu, X., Xie, J., Xie, M., & Zhao, J. (2020). Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. The Journal of allergy and clinical immunology, 146(1), 110–118.

McBane, R. D., 2nd, Torres Roldan, V. D., Niven, A. S., Pruthi, R. K., Franco, P. M., Linderbaum, J. A., Casanegra, A. I., Oyen, L. J., Houghton, D. E., Marshall, A. L., Ou, N. N., Siegel, J. L., Wysokinski, W. E., Padrnos, L. J., Rivera, C. E., Flo, G. L., Shamoun, F. E., Silvers, S. M., Nayfeh, T., Urtecho, M., … Murad, M. H. (2020). Anticoagulation in COVID-19: A Systematic Review, Meta-analysis, and Rapid Guidance From Mayo Clinic. Mayo Clinic proceedings, 95(11), 2467–2486.

Miesbach, W., & Makris, M. (2020). COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 26, 1076029620938149.

Minet, C., Potton, L., Bonadona, A., Hamidfar-Roy, R., Somohano, C. A., Lugosi, M., Cartier, J. C., Ferretti, G., Schwebel, C., & Timsit, J. F. (2015). Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis. Critical care (London, England), 19(1), 287.

Moores, L. K., Tritschler, T., Brosnahan, S., Carrier, M., Collen, J. F., Doerschug, K., ... & Wells, P. (2020). Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest, 158(3), 1143-1163.

Petrilli, C. M., Jones, S. A., Yang, J., Rajagopalan, H., O'Donnell, L., Chernyak, Y., Tobin, K. A., Cerfolio, R. J., Francois, F., & Horwitz, L. I. (2020). Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ (Clinical research ed.), 369, m1966.

Puelles, V. G., Lütgehetmann, M., Lindenmeyer, M. T., Sperhake, J. P., Wong, M. N., Allweiss, L., Chilla, S., Heinemann, A., Wanner, N., Liu, S., Braun, F., Lu, S., Pfefferle, S., Schröder, A. S., Edler, C., Gross, O., Glatzel, M., Wichmann, D., Wiech, T., Kluge, S., … Huber, T. B. (2020). Multiorgan and Renal Tropism of SARS-CoV-2. The New England journal of medicine, 383(6), 590–592.

Rico-Mesa, J. S., Rosas, D., Ahmadian-Tehrani, A., White, A., Anderson, A. S., & Chilton, R. (2020). The Role of Anticoagulation in COVID-19-Induced Hypercoagulability. Current cardiology reports, 22(7), 53.

Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020). Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive care medicine, 46(5), 846–848.

Salazar, M., Barochiner, J., Espeche, W., & Ennis, I. (2020). COVID-19, hipertensión y enfermedad cardiovascular [COVID-19 and its relationship with hypertension and cardiovascular disease]. Hipertension y riesgo vascular, 37(4), 176–180.

Shi, S., Qin, M., Shen, B., Cai, Y., Liu, T., Yang, F., Gong, W., Liu, X., Liang, J., Zhao, Q., Huang, H., Yang, B., & Huang, C. (2020). Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA cardiology, 5(7), 802–810.

Spyropoulos, A. C., Levy, J. H., Ageno, W., Connors, J. M., Hunt, B. J., Iba, T., Levi, M., Samama, C. M., Thachil, J., Giannis, D., Douketis, J. D., & Subcommittee on Perioperative, Critical Care Thrombosis, Haemostasis of the Scientific, Standardization Committee of the International Society on Thrombosis and Haemostasis (2020). Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. Journal of thrombosis and haemostasis: JTH, 18(8), 1859–1865.

Tang, N., Bai, H., Chen, X., Gong, J., Li, D., & Sun, Z. (2020). Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of thrombosis and haemostasis : JTH, 18(5), 1094–1099.

Thachil, J., Tang, N., Gando, S., Falanga, A., Cattaneo, M., Levi, M., Clark, C., & Iba, T. (2020). ISTH interim guidance on recognition and management of coagulopathy in COVID-19. Journal of thrombosis and haemostasis : JTH, 18(5), 1023–1026.

Touzé, E., Varenne, O., Chatellier, G., Peyrard, S., Rothwell, P. M., & Mas, J. L. (2005). Risk of myocardial infarction and vascular death after transient ischemic attack and ischemic stroke: a systematic review and meta-analysis. Stroke, 36(12), 2748–2755.

Weston, S., & Frieman, M. B. (2020). COVID-19: Knowns, Unknowns, and Questions. mSphere, 5(2), e00203-20.

Williamson, D. R., Albert, M., Heels-Ansdell, D., Arnold, D. M., Lauzier, F., Zarychanski, R., Crowther, M., Warkentin, T. E., Dodek, P., Cade, J., Lesur, O., Lim, W., Fowler, R., Lamontagne, F., Langevin, S., Freitag, A., Muscedere, J., Friedrich, J. O., Geerts, W., Burry, L., … PROTECT collaborators, the Canadian Critical Care Trials Group, and the Australian and New Zealand Intensive Care Society Clinical Trials Group (2013). Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes. Chest, 144(4), 1207–1215.

Wong, Y. J., Tan, M., Zheng, Q., Li, J. W., Kumar, R., Fock, K. M., Teo, E. K., & Ang, T. L. (2020). A systematic review and meta-analysis of the COVID-19 associated liver injury. Annals of hepatology, 19(6), 627–634.

Zhai, Z., Li, C., Chen, Y., Gerotziafas, G., Zhang, Z., Wan, J., Liu, P., Elalamy, I., Wang, C., & Prevention Treatment of VTE Associated with COVID-19 Infection Consensus Statement Group (2020). Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines. Thrombosis and haemostasis, 120(6), 937–948.

Zhang, J. J., Cao, Y. Y., Tan, G., Dong, X., Wang, B. C., Lin, J., Yan, Y. Q., Liu, G. H., Akdis, M., Akdis, C. A., & Gao, Y. D. (2021). Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients. Allergy, 76(2), 533–550.

Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., Guan, L., Wei, Y., Li, H., Wu, X., Xu, J., Tu, S., Zhang, Y., Chen, H., & Cao, B. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England), 395(10229), 1054–1062.

Downloads

Publicado

15/07/2022

Como Citar

OLIVEIRA, L. H. R. T. de .; REIS JUNIOR, N. A. dos .; GOMES, J. S.; SPÁRTALIS JUNIOR, P. B. .; MELLO, R. S. de .; SCHUELTER TREVISOL, F. Evolução clínica dos pacientes com COVID-10: impacto da anticoagulação. Research, Society and Development, [S. l.], v. 11, n. 9, p. e46611931423, 2022. DOI: 10.33448/rsd-v11i9.31423. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/31423. Acesso em: 23 nov. 2024.

Edição

v. 11 n. 9

Seção

Ciências da Saúde

Licença

Copyright (c) 2022 Laylla Hanna Rocha Torres de Oliveira; Nilton Almeida dos Reis Junior; José Sávio Gomes; Péricles Brasil Spártalis Junior; Rogério Sobroza de Mello; Fabiana Schuelter Trevisol

Creative Commons License
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.

Autores que publicam nesta revista concordam com os seguintes termos:

1) Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.

2) Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.

3) Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado.